Peer-Reviewed Review: 'Agentic' AI in Pathology Is Technically Promising, Not Clinically Proven
A new peer-reviewed review in Journal of Translational Medicine concludes that so-called agentic systems — which plan, reason and act autonomously — are not yet ready for the diagnostic bench. Authors Xinyu Lu and Susu Luo also offer a three-part taxonomy that could help researchers and regulators distinguish genuine autonomy from marketing.
A new review article published in Journal of Translational Medicine assesses whether autonomous, "agentic" AI architectures are ready for pathology's diagnostic bench — and the authors' answer is a carefully qualified no, according to bioengineer.org's coverage of the article. The work, led by Xinyu Lu of Shanghai Eastern Hepatobiliary Surgery Hospital and Susu Luo, who holds positions at the same hospital and at Moores Cancer Center at the University of California San Diego, is presented as one of the first systematic assessments of whether these architectures are ready for diagnostic use.
What "agentic" means in pathology
AI has already changed how pathologists examine tissue. Whole-slide imaging turned glass slides into gigapixel digital files, and deep learning models have learned to detect tumors, grade cancers and quantify biomarkers with remarkable accuracy, bioengineer.org writes. But the systems in current operation follow fixed analysis pipelines: the input passes through a predetermined sequence of processing steps.
Agentic systems are something else. The crucial difference is that the control flow is dynamic rather than predetermined. The system decides, moment by moment, which tool to call, which region of the slide to examine next, and when it has gathered enough evidence to render a judgment. Such systems can therefore plan, reason and act autonomously, with feedback loops that allow them to revise intermediate conclusions along the way.
Three pillars for evaluating the claims
The review's practical contribution is an operational taxonomy built on three pillars: dynamic control flow, inference-time tool selection and knowledge integration. These three characteristics, according to the authors, are what separate genuine agent architectures from conventional software marketed with the same words.
The framework is not merely technical. The term "agentic" has become as much a marketing buzzword as a technical term, applied to everything from simple chatbot wrappers to genuinely autonomous multi-model pipelines, according to bioengineer.org's account of the review. A shared terminology gives researchers and regulators a common yardstick for assessing whether a vendor's claim of "agentic" capability matches the system's actual behavior.
Why this is happening now
The assessment arrives amid a wave of marketing around the term "agentic" in the healthcare sector. Against that backdrop, the review offers a concrete tool for weighing vendor claims, and it positions itself as one of the first systematic evaluations of whether autonomous AI architectures are actually ready for pathological diagnostics.
The authors' conclusion is thus not a no to the technology, but a qualified no to its clinical maturity: technically promising, clinically unproven.
Open questions — and an important caveat
Several central details remain unresolved. AIMag has not verified the original article directly; the coverage rests on bioengineer.org's account, and neither the article's exact title nor its publication date can be confirmed against the original. Nor is it detailed which studies the review builds on, or what criteria the authors used to conclude that the systems are not clinically proven. The specific technical limitations the authors point to are likewise not documented in the available source material.
What remains is a clear framework and an equally clear warning: as far as pathology is concerned, autonomous planning and reasoning does not automatically mean clinical readiness — and the distance between the two is measured in evidence, not in marketing terms.